FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017939091> ?p ?o ?g. }

• W2017939091 endingPage "1098" @default.
• W2017939091 startingPage "1089" @default.
• W2017939091 abstract "Existing pharmacokinetic data are insufficient to determine whether a delayed-release formulation of mesalamine (Asacol) results in greater systemic exposure to 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid than a prodrug (balsalazide).To determine the pharmacokinetic parameters of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid from equimolar doses of 5-aminosalicylic acid administered as Asacol and balsalazide.Nineteen healthy volunteers completed an open-label, single-dose, randomized, crossover study comparing the pharmacokinetics of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid from equimolar doses of 5-aminosalicylic acid (800 mg) administered as Asacol (800 mg) and balsalazide (2250 mg). Plasma and urine samples were analysed for 5-aminosalicylic acid, N-acetyl-5-aminosalicylic acid, and balsalazide (urine only) using high-performance liquid chromatography methods with mass spectrometric detection. Pharmacokinetic parameters assessed for 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid included: percentage of dose excreted in urine (A(e)%), area under the plasma concentration-time curve (AUCt(last)); and maximum plasma concentration (C(max)).The geometric mean total (5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid) urinary excretion values (A(e)%) of Asacol and balsalazide were 19.26 and 19.31% (P = 0.98). The geometric mean A(e)% values of 5-aminosalicylic acid for Asacol and balsalazide were 0.39 and 0.37% (P = 0.78); the geometric mean A(e)% values of N-acetyl-5-aminosalicylic acid for Asacol and balsalazide were 18.78 and 18.83% (P = 0.98). The geometric mean 5-aminosalicylic acid AUC(t(last)) values for Asacol and balsalazide were 3295 and 3449 ng h/mL (P = 0.85); the geometric mean N-acetyl-5-aminosalicylic acid AUC(t(last)) values for Asacol and balsalazide were 15 364 and 16 050 ng h/mL (P = 0.69). The geometric mean 5-5-aminosalicylic acid C(max) values for Asacol and balsalazide were 319 and 348 ng/mL (P = 0.80); the geometric mean N-acetyl-5-aminosalicylic acid C(max) values for Asacol and balsalazide 927 and 1009 ng/mL (P = 0.67).The systemic absorption of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid from Asacol and balsalazide are comparable based upon plasma pharmacokinetic parameters and urinary excretion values." @default.
• W2017939091 created "2016-06-24" @default.
• W2017939091 creator A5027765330 @default.
• W2017939091 creator A5028248246 @default.
• W2017939091 creator A5032150391 @default.
• W2017939091 date "2004-05-01" @default.
• W2017939091 modified "2023-10-14" @default.
• W2017939091 title "Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers¹" @default.
• W2017939091 cites W1770909803 @default.
• W2017939091 cites W1973960461 @default.
• W2017939091 cites W1981461721 @default.
• W2017939091 cites W1989738331 @default.
• W2017939091 cites W2004141560 @default.
• W2017939091 cites W2009300212 @default.
• W2017939091 cites W2022752808 @default.
• W2017939091 cites W2025160331 @default.
• W2017939091 cites W2033317644 @default.
• W2017939091 cites W2040547481 @default.
• W2017939091 cites W2053585254 @default.
• W2017939091 cites W2068641994 @default.
• W2017939091 cites W2068787312 @default.
• W2017939091 cites W2075833014 @default.
• W2017939091 cites W2093597086 @default.
• W2017939091 cites W2096326818 @default.
• W2017939091 cites W2097224532 @default.
• W2017939091 cites W2118585077 @default.
• W2017939091 cites W2124177455 @default.
• W2017939091 cites W2129694146 @default.
• W2017939091 cites W2132688718 @default.
• W2017939091 cites W2147825834 @default.
• W2017939091 cites W2161667176 @default.
• W2017939091 cites W2165763417 @default.
• W2017939091 cites W2321205867 @default.
• W2017939091 cites W2435135945 @default.
• W2017939091 cites W267429781 @default.
• W2017939091 cites W4236303975 @default.
• W2017939091 cites W47417504 @default.
• W2017939091 doi "https://doi.org/10.1111/j.1365-2036.2004.01964.x" @default.
• W2017939091 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15142198" @default.
• W2017939091 hasPublicationYear "2004" @default.
• W2017939091 type Work @default.
• W2017939091 sameAs 2017939091 @default.
• W2017939091 citedByCount "27" @default.
• W2017939091 countsByYear W20179390912012 @default.
• W2017939091 countsByYear W20179390912013 @default.
• W2017939091 countsByYear W20179390912014 @default.
• W2017939091 countsByYear W20179390912015 @default.
• W2017939091 countsByYear W20179390912019 @default.
• W2017939091 countsByYear W20179390912020 @default.
• W2017939091 countsByYear W20179390912021 @default.
• W2017939091 countsByYear W20179390912022 @default.
• W2017939091 crossrefType "journal-article" @default.
• W2017939091 hasAuthorship W2017939091A5027765330 @default.
• W2017939091 hasAuthorship W2017939091A5028248246 @default.
• W2017939091 hasAuthorship W2017939091A5032150391 @default.
• W2017939091 hasConcept C112705442 @default.
• W2017939091 hasConcept C126322002 @default.
• W2017939091 hasConcept C142724271 @default.
• W2017939091 hasConcept C185592680 @default.
• W2017939091 hasConcept C204787440 @default.
• W2017939091 hasConcept C27081682 @default.
• W2017939091 hasConcept C2776206795 @default.
• W2017939091 hasConcept C2777477808 @default.
• W2017939091 hasConcept C2779134260 @default.
• W2017939091 hasConcept C2779174533 @default.
• W2017939091 hasConcept C2780026642 @default.
• W2017939091 hasConcept C2780479503 @default.
• W2017939091 hasConcept C71924100 @default.
• W2017939091 hasConcept C87813604 @default.
• W2017939091 hasConcept C90924648 @default.
• W2017939091 hasConcept C98274493 @default.
• W2017939091 hasConceptScore W2017939091C112705442 @default.
• W2017939091 hasConceptScore W2017939091C126322002 @default.
• W2017939091 hasConceptScore W2017939091C142724271 @default.
• W2017939091 hasConceptScore W2017939091C185592680 @default.
• W2017939091 hasConceptScore W2017939091C204787440 @default.
• W2017939091 hasConceptScore W2017939091C27081682 @default.
• W2017939091 hasConceptScore W2017939091C2776206795 @default.
• W2017939091 hasConceptScore W2017939091C2777477808 @default.
• W2017939091 hasConceptScore W2017939091C2779134260 @default.
• W2017939091 hasConceptScore W2017939091C2779174533 @default.
• W2017939091 hasConceptScore W2017939091C2780026642 @default.
• W2017939091 hasConceptScore W2017939091C2780479503 @default.
• W2017939091 hasConceptScore W2017939091C71924100 @default.
• W2017939091 hasConceptScore W2017939091C87813604 @default.
• W2017939091 hasConceptScore W2017939091C90924648 @default.
• W2017939091 hasConceptScore W2017939091C98274493 @default.
• W2017939091 hasIssue "10" @default.
• W2017939091 hasLocation W20179390911 @default.
• W2017939091 hasLocation W20179390912 @default.
• W2017939091 hasOpenAccess W2017939091 @default.
• W2017939091 hasPrimaryLocation W20179390911 @default.
• W2017939091 hasRelatedWork W188767024 @default.
• W2017939091 hasRelatedWork W1984317973 @default.
• W2017939091 hasRelatedWork W2058680921 @default.
• W2017939091 hasRelatedWork W2079851763 @default.
• W2017939091 hasRelatedWork W2157946389 @default.
• W2017939091 hasRelatedWork W2317987634 @default.

• next